ArticleAnnals of nuclear medicine2025
The prognostic role of staging [18F]PSMA-1007 PET/CT volumetric and dissemination features in prostate cancer.
Article in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy and safety of [Frontiers in medicine · 2026Pooled it
- Detection rate of [Frontiers in medicine · 2026Pooled it
- The prognostic role of maximum tumor dissemination derived by PET/CT in oncological diseases: a systematic review.Frontiers in medicine · 2025Pooled it
- Head-to-head comparison ofEJNMMI research · 2026Article
- The predictive and prognostic role of baseline 2-[18F]FDG PET/CT volumetric and dissemination features in classical Hodgkin lymphoma.European journal of nuclear medicine and molecular imaging · 2026Article
- Prognostic value of lesion dissemination onQuantitative imaging in medicine and surgery · 2026Article
- Biomarkers for Precision Prognosis in Prostate Cancer: Imaging, Molecular, and Integrated Approaches.Cancers · 2026Review
- Article
- The Role of Radiomics and Artificial Intelligence Applied to Staging PSMA PET in Assessing Prostate Cancer Aggressiveness.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed the role of volumetric and dissemination features of staging [18F]PSMA-1007 PET/CT in predicting progression-free survival (PFS) in patients with prostate cancer (PCa) and their relationship with the main clinical data (ISUP grade groups, number of lesions, PSA).
methodsWe included 164 patients with high-risk PCa who underwent baseline [18F]PSMA-1007 PET/CT. With the help of LIFEx version 7.7, the main volumetric and dissemination PET parameters were semi-automatically extracted: PSMA-prostate tumor volume (PSMA-TV), PSMA-prostate total lesion (PSMA-TL), PSMA total TV (PSMA-TTV), PSMA total TL (PSMA-TTL) and Dmax corrected for body-surface-area (Dmax
resultsA high correlation was seen between the number of lesions and both PSMA-TTL (r 0.725), and Dmaxbsa (r 0.935). A moderate correlation was registered between PSA and PSMA-TTV (r 0.333), PSMA-TTL (r 0.441), Dmax
conclusionVolumetric and dissemination features derived by staging [18F]PSMA-1007 PET/CT were significantly correlated with PSA and number of lesions. The combination of PSMA-TTL and Dmax
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.